Pharmacological treatments, including insulin sensitizers like metformin (9), vitamin E (10), and emerging anti-obesity agents like glucagon-like peptide-1 (GLP-1) agonists and sodium-glucose cotransporter-2 (SGLT-2) inhibitors (11, 12), can also be used to address metabolic disturbances. Here, SLC5A2 is linked to obesity due to melanocortin 4 receptor deficiency.